Voxilaprevir: Difference between revisions

Voxilaprevir
Clinical data
Trade names	Vosevi (combination with sofosbuvir and velpatasvir)
Identifiers
	IUPAC name (1R,18R,20R,24S,27S,28S)-N-[(1R,2R)-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide;
CAS Number	1535212-07-7;
PubChem CID	89921642;
ChemSpider	44209500;
UNII	0570F37359;
KEGG	D10899;
Chemical and physical data
Formula	C40H52F4N6O9S
Molar mass	868.94 g·mol−1
3D model (JSmol)	;
Density	1.4±0.1 g/cm3
	SMILES CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C;
	InChI InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1; Key:MZBLZLWXUBZHSL-FZNJKFJKSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 20:33, 26 May 2019

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.^[2]

On 18 July 2017, Vosevi was approved by Food and drug administration.^[3]

References

^ "voxilaprevir_msds".
^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
^ FDA approves Vosevi for Hepatitis C

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[chemsrc-1] "voxilaprevir_msds".

[2] "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.

[3] FDA approves Vosevi for Hepatitis C

[1]

[2]

[3]

@@ Line 5: / Line 5: @@
 | image = Voxilaprevir.svg
 | alt =
-| caption = <!-- Clinical data -->
+| caption =
+<!-- Clinical data -->
 | pronounce =
 | tradename = Vosevi (combination with [[sofosbuvir]] and [[velpatasvir]])
@@ Line 26: / Line 27: @@
 | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
 | legal_status = <!-- Free text -->
-<!-- Pharmacokinetic data -->| bioavailability =
+<!-- Pharmacokinetic data -->
+| bioavailability =
 | protein_bound =
 | metabolism =
@@ Line 33: / Line 35: @@
 | elimination_half-life =
 | duration_of_action =
-| excretion = <!-- Identifiers -->
+| excretion =
+<!-- Identifiers -->
 | CAS_number = 1535212-07-7
 | class =
@@ Line 44: / Line 47: @@
 | UNII = 0570F37359
 | KEGG = D10899
-<!-- Chemical and physical data -->| chemical_formula =
+<!-- Chemical and physical data -->
+| C = 40 | H = 52 | F = 4 | N = 6 | O = 9 | S = 1
-| C = 40
-| H = 52
-| F = 4
-| N = 6
-| O = 9
-| S = 1
-| molecular_weight =
 | smiles = CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C
 | StdInChI = 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
 | StdInChIKey = MZBLZLWXUBZHSL-FZNJKFJKSA-N
 | density = 1.4±0.1<ref name="chemsrc">{{Cite web|url=https://www.chemsrc.com/en/cas/1535212-07-7_1287459.html|title=voxilaprevir_msds}}</ref>
+| Jmol=None
 }}